DoW Peer Reviewed Medical, Research Advancement Award

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Research Advancement Award supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals. Distinctive Features: Applications must include preliminary data. The Research Advancement Award supports use-inspired basic research to further or validate preliminary findings for short- and long-term impact. Proposed research projects may range from hypothesis testing to expansion of mature data. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $19.6M to fund approximately 14 Research Advancement Award applications with total cost caps of $1.4M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.